Dr. John M. Strother, M.D
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Pennsylvania State University College of Medicine (2000)
- Years since graduation
- 26
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 631
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2000Medical school: Pennsylvania State University College of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
OR license MD23542 -
Hematology (Internal Medicine) Physician
OR license MD22929
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Salem Hospital Salem, OR
- Good Samaritan Regional Medical Center Corvallis, OR
- Samaritan Albany General Hospital Albany, OR
- Samaritan Lebanon Community Hospital Lebanon, OR
- Salem Health West Valley Dallas, OR
Medical groups
- Good Samaritan Hospital Corvallis (380 clinicians)
- Albany General Hospital (198 clinicians)
- Oregon Oncology Specialists LLP (41 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 631
- Services billed
- 134,026
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Injection, oxaliplatin, 0.5 mg | 15,400 | 12 |
| Injection, fosaprepitant, 1 mg | 13,200 | 27 |
| Injection, bortezomib, 0.1 mg | 2,983 | 11 |
| Injection, dexamethasone sodium phosphate, 1 mg | 1,612 | 57 |
| Injection, palonosetron hcl, 25 mcg | 1,000 | 35 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 747 | 218 |
| Blood test, comprehensive group of blood chemicals | 706 | 208 |
| Injection, ondansetron hydrochloride, per 1 mg | 656 | 32 |
| Established patient office or other outpatient visit, 30-39 minutes | 590 | 253 |
| Insertion of needle into vein for collection of blood sample | 520 | 175 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Anastrozole Other prescribers in Salem, OR | 282 |
| Gabapentin Other prescribers in Salem, OR | 108 |
| Hydroxyurea Other prescribers in Salem, OR | 108 |
| Tamoxifen Citrate Other prescribers in Salem, OR | 103 |
| Prochlorperazine Maleate Other prescribers in Salem, OR | 96 |
| Acyclovir Other prescribers in Salem, OR | 77 |
| Eliquis (apixaban) Other prescribers in Salem, OR | 70 |
| Abiraterone Acetate | 69 |
| Levothyroxine Sodium Other prescribers in Salem, OR | 65 |
| Oxycodone Hcl Other prescribers in Salem, OR | 63 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 14 companies reported 26 payments worth $668 in total to this clinician.
| Beone Medicines USA, Inc. | $202 |
|---|---|
| Pfizer Inc. | $107 |
| GlaxoSmithKline, LLC. | $73.98 |
| Novartis Pharmaceuticals Corporation | $44.49 |
| Merck Sharp & Dohme LLC | $38.53 |
| AbbVie Inc. | $28.25 |
| AstraZeneca Pharmaceuticals LP | $26.57 |
| Jazz Pharmaceuticals Inc. | $24.58 |
| Food and Beverage | $481 |
|---|---|
| Travel and Lodging | $167 |
| Education | $20.00 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Beone Medicines USA, Inc. Oct 26, 2025 | Travel and Lodging travel to Salem, Mexico | $72.00 |
| Beone Medicines USA, Inc. Oct 26, 2025 | Travel and Lodging travel to Salem, Mexico | $47.60 |
| Beone Medicines USA, Inc. Oct 29, 2025 | Travel and Lodging travel to Salem, Mexico | $47.60 |
| Aveo Pharmaceuticals, Inc. Mar 6, 2025 | Education FOTIVDA · Oncology · in-kind | $20.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 6 companies. The companies reported $230,292 in research payments for these studies, mostly to the institutions running them.
- A Randomized, Open label, Phase 3 Study of MK-2870 in Combination with Pembrolizumab Compared to Pembrolizumab Monotherapy in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer with PD…
Merck Sharp & Dohme LLC - A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Beone Medicines Ltd. · Recruiting · NCT07043400 - A phase 3, randomized, double-blind, placebo-controlled study of LY4064809 combined with a CDK4/6 inhibitor and endocrine therapy in adults with hr+, HER2- advanced breast cancer with a PIK3CA mutation who received no…
Eli Lilly and Company - A Phase 3 Study Comparing Daratumumab VELCADE bortezomib Lenalidomide and Dexamethasone DVRd with VELCADE Lenalidomide and Dexamethasone VRd in Subjects with Untreated Multiple Myeloma and for Whom Hematopoietic Stem …
Janssen Research & Development, LLC - Connect Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry. The purpose of the Connect Myeloid disease registry is to provide unique insights into treatm…
Celgene Corporation - BNT327
BioNTech SE
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.